Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis
2 other identifiers
observational
55
1 country
1
Brief Summary
This is an exploratory study in which the investigators will develop a way to identify the cell responses most strongly associated with protection against chlamydia infection. This study is not driven by a hypothesis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2009
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 29, 2009
CompletedFirst Posted
Study publicly available on registry
September 2, 2009
CompletedStudy Start
First participant enrolled
December 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedApril 7, 2017
April 1, 2017
6 months
August 29, 2009
April 5, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
This is an exploratory investigation in which we will develop the methodology needed to identify the antigen-specific cell mediated immune responses most strongly associated with protection against incident C. trachomatis infection.
1 year
Study Arms (2)
history of chlamydia infection
Women who self-reported a history of cervical infection with Chlamydia trachomatis
no history of chlamydia infection
Women who self-reported no history of cervical infection with Chlamydia trachomatis
Eligibility Criteria
20 women with history of endocervical chlamydia and 10 women with no history of endocervical chlamydia
You may qualify if:
- Women between 15-35 years of age at the time of enrollment onto this study. Minors between the ages of 1-17 will require parental consent to participate in the study.
- History of, in past 5 years, endocervical C. trachomatis infection (total of 20 women) or no history of endocervical C. trachomatis infection (total of 10 women).
You may not qualify if:
- Pregnancy.
- Immunocompromised, by history (including but not limited to known HIV, cancer, autoimmune diseases).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas L Cherpes, MD
University of Pittsburgh
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 29, 2009
First Posted
September 2, 2009
Study Start
December 1, 2009
Primary Completion
June 1, 2010
Study Completion
June 1, 2010
Last Updated
April 7, 2017
Record last verified: 2017-04
Data Sharing
- IPD Sharing
- Will not share